A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE-FINDING, PHARMACOKINETIC, SAFETY AND TOLERABILITY STUDY OF PF-07265807 IN PARTICIPANTS WITH SELECTED ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES

A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as
Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors

Inclusion Criteria:

- At least one measurable (Parts 1-4) or non-measurable lesion (Parts 1-3), not
previously irradiated, as defined by RECIST 1.1

- ECOG Performance Status 0 or 1, 2 with approval

- Adequate Bone Marrow Function

- Adequate Renal Function

- Adequate Liver Function

- Resolved acute effects of any prior therapy

- Able to provide adequate archival tumor tissue or freshly obtained tumor tissue (some
participants will require mandatory pre- and on-treatment biopsy is part of the
biomarker cohort).

- Life expectancy of at least 3 months.

- Part 1 and Part 2: Participants who are intolerant or resistant to standard treatment
for selected solid tumors.

- Part 3: Participants with advanced/metastatic RCC with a clear cell component and
progressed with no standard therapy available.

- Part 4, Cohort 1: Participants with NSCLC with METex14-skipping alteration(s) and
progressed on at least 1 prior therapy.

- Part 4, Cohort 2: Participants with MSS CRC with intermediate TMB and progressed with
no satisfactory alternative treatment available, but has not received prior treatment
with an anti-PD-(L)1 therapy.

- Part 4, Cohort 3: Participants with metastatic gastric or GEJ adenocarcinoma that is
PD-L1 positive that has progressed on at least 2 but no more than 3 prior chemotherapy
regiments, but has not received prior treatment with an anti-PD-(L)1 therapy.

- Part 4, Cohort 4: Participants with metastatic RCC with a clear cell component with
IMDC intermediate or poor risk that have not received any prior systemic therapy for
metastatic disease.

Exclusion Criteria:

- Known active uncontrolled or symptomatic CNS metastases.

- Any other active malignancy within 2 years prior to enrollment.

- Major surgery within 6 weeks, radiation therapy within 4 weeks, systemic anti-cancer
therapy within 2 week or 5 half-lives (4 weeks or 5 half-lives for antibody therapies
or investigational drug(s) taken on another study) prior to study entry.

- Active or history of autoimmune disease requiring >10mg/day prednisone or other
concurrent immunosuppressive therapy.

- Active, uncontrolled infection (controlled HBV, HCV, HIV/AIDS may be allowed) as
defined in protocol.

- Retinal or other serious ophthalmic disorders as defined in protocol.

- Clinically significant cardiac disease as defined in protocol.

- Uncontrolled HTN that cannot be controlled by medications.

- Inability to consume or absorb study drug.

- Known or suspected hypersensitivity to PF-07265807.

- Prohibited concomitant medications as defined in protocol.

- Active inflammatory GI disease, uncontrollable chronic diarrhea, or previous gastric
resection or lap band surgery affecting absorption.

- Active bleeding disorder.

- Discontinuation of prior checkpoint inhibitor for treatment-related toxicity.

- Experienced >= G3 treatment-related irAE with prior PD-(L)1 agent.

- Prior treatment with selective AXL/MERTK inhibitors

For participants receiving sasanlimab:

- Known history of non-infectious pneumonitis that required steroid treatment or current
pneumonitis.